Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Bioline RX Ltd ($BLRX) stock jumped 5.10% in its previous trading session to close at $1.03. The stock has gained 3% in the past six months. The company announced the results of a Phase 2a clinical trial for its lead product candidate BL-8040 The data showed that the treatment resulted in a 38% complete remission rate, superior to the historical rate for chemo agent cytarabine, in patients suffering from acute myeloid leukemia (AML).
BL-8040 is a synthetic peptide that binds to a protein found on the surface of cancer cells called CXCR4, a chemokine receptor that that plays a key role in tumor growth and survival.

AbbVie ($ABBV) announced that it has signed a new agreement with Johns Hopkins University School of Medicine. The five-year long collaboration will focus on developing medical oncology research and discovery at both organizations.
Both the organizations will launch a joint steering committee for deciding on the projects to be undertaken. Researchers from both the organizations will also take part in an annual symposium for discussing their joint research and for the purpose of evaluating their new projects. AbbVie will provide its new therapies to the researchers from the Johns Hopkins University School of Medicine. The company will also have the option of securing exclusive license to some of the discoveries made by Hopkins School under this contract.

 

• Dr. Reddy's Laboratories ($RDY) announced the launch of generic versions of Taro Pharmaceuticals' Nystatin and Triamcinolone Acetonide Cream, USP in the United States. IMS Health estimates the U.S. market for the products to be nearly $120M.
• Bloomberg reports that Sanofi ($SNY) may be considering a bid for Actelion, which is currently negotiating a deal with Johnson & Johnson for $250 per share.

• Adaptimmune Therapeutics ($ADAP) announced the start of an open-label trial of its NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma (MRCLS). The 15-subject pilot study aims to evaluate preliminary safety and efficacy in this new indication. Results will be used for supporting a future registration trial.
• Bellicum Pharmaceuticals ($BLCM) announced positive results from the BP-004 study for the evaluation of its lead product candidate BPX-501 in children with primary immune deficiencies (PID) and hemoglobinopathies. BPX-501, an adjunct T cell therapy administered after a hematopoietic stem cell transplant, comprises genetically modified donor T cells incorporating the company's CaspaCIDe safety switch.

 

• AstraZeneca ($AZN) has finalized its agreement with Johnson & Johnson's (NYSE:JNJ) Cilag GmbH International for the divestment of the ex-U.S. rights to Rhinocort Aqua, a nasal spray for allergic and non-allergic rhinitis and nasal polyps.
• Novelion Therapeutics ($NVLN) announced signing a licensing agreement with London-based Amryt Pharma for the exclusive distribution rights to LOJUXTA (lomitapide) in the European Economic Area, Switzerland, Turkey and certain Middle Eastern and North African countries, including Israel. The deal has been entered through its subsidiary Aegerion Pharmaceuticals.

 

• GW Pharmaceuticals ($GWPH) reported its earnings for the fourth quarter at GBP 0.06 per share. Its revenue for the quarter stood at GBP 1.67 million, down 70.2% on year over year basis.

• The Medicines Company ($MDCO) received initial raring of Buy from H.C. Wainwright. The price target for the stock has been set at $57.

Gainers (% price change) Last Trade Change Mkt Cap
Dynavax Tech. Corp.
DVAX (NASDAQ)
5.15 +0.45 (9.57%) 214.38M
Enzo Biochem, Inc.
ENZ (NYSE)
7.25 +0.58 (8.70%) 338.57M
Celldex Therapeutics, Inc
CLDX (NASDAQ)
3.79 +0.24 (6.76%) 381.58M
ImmunoGen, Inc.
IMGN (NASDAQ)
2.00 +0.12 (6.38%) 185.45M
STAAR Surgical Company
STAA (NASDAQ)
11.15 +0.65 (6.19%) 440.21M
Losers (% price change)
Omnicell, Inc.
OMCL (NASDAQ)
34.35 -2.10 (-5.76%) 1.28B
Flamel Tech. S.A. (ADR)
FLML (NASDAQ)
10.57 -0.42 (-3.82%) 445.24M
China Cord Blood Corp
CO (NYSE)
4.65 -0.18 (-3.73%) 329.24M
Osiris Therapeutics, Inc.
OSIR (NASDAQ)
5.47 -0.21 (-3.70%) 190.47M
Omeros Corporation
OMER (NASDAQ)
10.56 -0.35 (-3.21%) 437.16M
Most Actives (dollar volume)
UnitedHealth Group Inc
UNH (NYSE)
157.63 -3.10 (-1.93%) 149.84B
Merck & Co., Inc.
MRK (NYSE)
60.25 -0.88 (-1.44%) 167.13B
Gilead Sciences, Inc.
GILD (NASDAQ)
72.36 -0.06 (-0.08%) 94.78B
Johnson & Johnson
JNJ (NYSE)
111.94 -0.02 (-0.02%) 306.12B
Pfizer Inc.
PFE (NYSE)
31.59 -0.04 (-0.13%) 192.74B